Search results

57 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
New insights into side effects can help prostate cancer patients choose treatments
In the Journal of the American Medical Association, a study led by UNC Lineberger member Ronald C. Chen, MD, examines quality-of-life outcomes for modern treatment choices most patients will face, including active surveillance, radical prostatectomy, external beam radiation treatment, and brachytherapy.
Located in News
Researchers awarded grant to study strategy to improve immunotherapy response
With a $1.74 million grant from the NIH, UNC Lineberger researchers led by H. Shelton Earp, MD, will study a potential new strategy for improving immunotherapy drug responses in patients with melanoma.
Located in News
Patients and their records agree on medical history for most maladies
A study led by UNC Lineberger researcher Ronald Chen, MD, found that a group of prostate cancer patients reliably reported their own medical histories when their responses were compared to their medical records.
Located in News
Located in Newsroom / UNC Lineberger in the News
'Good' bacteria is possible solution for unchecked inflammation in bowel diseases
In a study published in journal Nature Immunology, researchers led by UNC Lineberger member Jenny P.Y. Ting, PhD, described how inflammation can go unchecked in the absence of a certain inflammation inhibitor called NLRP12. In a harmful feedback loop, this inflammation can upset the balance of bacteria living in the gut. Beneficial bacteria may be the key to reversing inflammation in the absence of this key regulator.
Located in News
Located in Newsroom / UNC Lineberger in the News
Cost, technology issues are barriers to real-time cancer patient symptom reporting
In a perspective published in the New England Journal of Medicine, UNC Lineberger member Ethan Basch, MD, MSc, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.
Located in News
UNC Lineberger launches innovative cellular immunotherapy program
UNC Lineberger, with its U.S. FDA-approved Good Manufacturing Practices, or “clean,” facility, is one of only a select academic centers in the United States with the capability to genetically modify patient immune cells for clinical use. This makes it possible for people who live in the Southeastern U.S. to stay closer to home to undergo cellular immunotherapy treatment.
Located in News
Located in Newsroom / UNC Lineberger in the News
Located in Newsroom / UNC Lineberger in the News